近日，来自麦吉尔大学的研究者们在Cancer Res杂志上发表了题为“Co-targeting CDK4/6 and BRD4 promotes senescence and ferroptosis sensitivity in cancer”的文章 ...

Astrocytomas are the most common primary cancer affecting the central ... due to the insensitivity of the human anti-CDK4 antibodies for immunohistochemistry (data not shown).

BUFFALO, NY- December 2, 2022 – A new review was published in Genes & Cancer on August 25, 2022, entitled, “CDK4: a master regulator of the cell cycle and its role in cancer.” The mammalian ...

The Diehl lab also explores the interconnections of lipid signaling, epigenetic regulation and the role of the unfolded protein response within tumor progression. One major focus of Dr. Diehl’s ...

Median PFS almost doubled with the CDK4/6 inhibitor-endocrine combination ... endocrine-refractory HR-positive breast cancer with HER2-low status (IHC 1+ or IHC 2+/in situ hybridization negative).

CDK4/6 inhibitors, which are already FDA approved for the treatment of other forms of cancer, show early signs of promise in the treatment of a subtype of pediatric high-grade glioma, according to ...

In luminal breast cancer, targeted therapy inhibits CDK4/6 proteins, which control growth rate and division of cells. The approval of these inhibitors was a breakthrough in the treatment of ...

When CDKs become overexpressed or dysregulated, they can drive tumor formation. Since 2015, the U.S. Food and Drug Administration has approved three drugs to inhibit CDK4 and 6 (Palbociclib, ...

And the three abstracts that I reviewed included the LEONARDA-1 study, which investigated the use of a new CDK4/6 inhibitor by the name of lerociclib in patients with metastatic breast cancer who ...

Researchers took a deep look at tumor samples from patients with diffuse hemispheric glioma and discovered an unexpected vulnerability to CDK4/6 inhibitors. CDK4/6 inhibitors, which are already ...